Clearbridge Investments, LLC Alnylam Pharmaceuticals, Inc. Transaction History

Clearbridge Investments, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$185.01 - $212.05 $1.28 Million - $1.47 Million	6,911 Added 9.06%	83,185 $15.8 Million
Q1 2023 May 12, 2023	BUY	$182.66 - $235.53 $3.58 Million - $4.62 Million	19,614 Added 34.62%	76,274 $15.3 Million
Q4 2022 Feb 10, 2023	BUY	$185.53 - $241.31 $10.5 Million - $13.7 Million	56,660 New	56,660 $13.5 Million
Q3 2020 Nov 12, 2020	SELL	$121.19 - $165.49 $44,234 - $60,403	-365 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$93.12 - $133.99 $1,117 - $1,607	-12 Reduced 3.18%	365 $40,000
Q2 2018 Aug 14, 2018	SELL	$88.31 - $107.8 $154,100 - $188,111	-1,745 Reduced 82.23%	377 $37,000
Q1 2018 May 15, 2018	SELL	$115.92 - $148.54 $45,672 - $58,524	-394 Reduced 15.66%	2,122 $253,000
Q4 2017 Feb 14, 2018	SELL	$114.49 - $139.98 $171,963 - $210,249	-1,502 Reduced 37.38%	2,516 $320,000
Q3 2017 Nov 14, 2017	SELL	$72.53 - $118.27 $15,884 - $25,901	-219 Reduced 5.17%	4,018 $472,000
Q2 2017 Aug 14, 2017	BUY	N/A	4,237	4,237 $338,000

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Clearbridge Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Clearbridge Investments, LLC with notifications on news.